SCHEMBL22291498

SCHEMBL22291498

O=C1CCC(N2C(=O)c3ccc(N4CCC(CCN5CCN(C(=O)O)CC5)CC4)cc3C2=O)C(=O)N1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 18/20 0.63
▸ CCNC P24863 1/20 0.53
▸ CDK8 P49336 1/20 0.53
▸ IRAK1 P51617 1/20 0.53
▸ NTRK3 Q16288 1/20 0.53
▸ HASPIN Q8TF76 1/20 0.53
▸ CDK19 Q9BWU1 1/20 0.53
▸ IRAK4 Q9NWZ3 1/20 0.53
▸ IRAK3 Q9Y616 1/20 0.53
▸ HPGDS O60760 2/20 0.53
▸ DDB1 Q16531 7/20 0.50
▸ ITK Q08881 3/20 0.50
▸ IL2 P60568 1/20 0.50
▸ AR P10275 2/20 0.49
▸ BTK Q06187 2/20 0.47
▸ RAF1 P04049 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645553 0.90 CRBN (0.61) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL22291366 0.88 CRBN (0.54) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL22498026 0.88 CRBN (0.77) CRBNHPGDSDDB1
SCHEMBL27176462 0.88 CRBN (0.65) CRBNIRAK1IRAK4IRAK3HPGDS
SCHEMBL22291391 0.87 CRBN (0.67) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL29596434 0.87 CRBN (0.60) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL23705474 0.86 CRBN (0.62) CRBNIRAK1IRAK4IRAK3DDB1
SCHEMBL29648377 0.85 CRBN (0.67) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL24501729 0.85 CRBN (0.67) CRBNCCNCCDK8IRAK1NTRK3
SCHEMBL22290046 0.85 CRBN (0.67) CRBNCCNCCDK8IRAK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391686-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-19 — — US disclosed
US-20230077730-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-03-16 — — US disclosed
CN-113874016-A Compound and use thereof 福宏治疗公司 2021-12-31 — — CN disclosed
EP-3917526-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
WO-2020160192-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230077730-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 CRBN 56/4885CCNC 2362/4885CDK8 1410/4885
US-12391686-B2 Compounds and uses thereof VHL, TFEB, BECN1 CRBN 56/4885CCNC 2362/4885CDK8 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback